Cellivery Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.

Top 17 shareholders own 20.06% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
13.9%	Daewoong Jo	5,099,454	₩34.1b	0%	no data
2.29%	The Vanguard Group, Inc.	838,278	₩5.6b	0%	no data
1.34%	BlackRock, Inc.	490,504	₩3.3b	0%	no data
1.06%	Samsung Asset Management Co., Ltd.	389,012	₩2.6b	0%	0.01%
0.57%	Norges Bank Investment Management	208,586	₩1.4b	0%	no data
0.33%	Mirae Asset Global Investments Co., Ltd	122,359	₩817.4m	0%	no data
0.12%	Charles Schwab Investment Management, Inc.	45,216	₩302.0m	0%	no data
0.11%	Seonhong Kwon	40,000	₩267.2m	0%	no data
0.1%	State Street Global Advisors, Inc.	37,185	₩248.4m	0%	no data
0.091%	KB Asset Management Co., Ltd.	33,367	₩222.9m	0%	no data
0.078%	Teachers Insurance and Annuity Association-College Retirement Equities Fund	28,469	₩190.2m	0%	no data
0.031%	NH-Amundi Asset Management Co.,Ltd.	11,452	₩76.5m	6.62%	no data
0.021%	Byeonghwa Lee	7,600	₩50.8m	0%	no data
0.0048%	Hanwha Asset Management Co. Ltd.	1,762	₩11.8m	0%	no data
0.0028%	HSBC Global Asset Management (UK) Limited	1,042	₩7.0m	0%	no data
0.00054%	Kyobo AXA Investment Managers Co, Ltd.	198	₩1.3m	0%	no data
0.00052%	Invesco Capital Management LLC	190	₩1.3m	0%	no data